|
|
|
|
|
|
|
08.05.26 - 19:27
|
Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher (ZeroHedge)
|
|
|
Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher
Moderna is out with timely news that it is working on early-stage research on vaccines targeting hantaviruses. The news comes as a Spanish woman has been hospitalized for a suspected infection, while a hantavirus cluster has ravaged a Dutch-flagged cruise ship, with five confirmed and three suspected cases of hantavirus. Three deaths have been reported so far.
Bloomberg reports that Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases on hantavirus vaccine research and is also working with Korea University College of Medicine's Vaccine Innovation Center on a potential vaccine.
"These efforts are early-stage and ongoing and reflect Moderna's broader responsibility to develop countermeasures against emerging infectious diseases," Moderna said.
Moderna said its work on hantavirus vaccines began before the cruise ship Hondius reported an outbreak while anchored off the...
|
|
|
|
|
|
|
08.05.26 - 18:12
|
Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an (Der Aktionaer)
|
|
|
Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus Angst vor einer weiteren Ausbreitung wird die Aktie von Moderna an der Börse gespielt....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 16:24
|
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era (24/7 Wall St.)
|
|
|
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs. Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life ... Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era...
|
|
|
|
|
|
|
|
|
|
|
|
|
|